Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only five percent. Despite this poor prognosis, SCLC is initially highly responsive ...

Three DDR phenotypes in SCLC influence chemotherapy response and resistance, impacting patient outcomes. Higher DDR activity correlates with initial chemotherapy sensitivity but leads to rapid ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

Implementation of tarlatamab treatment for small cell lung cancer using an outpatient care program. A prospective, single-arm, phase II trial of adebrelimab plus nab-paclitaxel and carboplatin in ...

SCLC is more aggressive than NSCLC, characterized by rapid growth and early metastasis, leading to poorer outcomes. Limited-stage SCLC is confined to one hemithorax, while extensive-stage involves ...

The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response rate over a ...

Circulating tumor DNA (ctDNA) may help personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC), according to a study from China. Researchers ...

Small cell lung cancer (SCLC) often responds well to initial treatment before later relapsing. Researchers are continuing to investigate new treatments, such as targeted therapy and immunotherapy ...

The IMforte trial showed Zepzelca plus Tecentriq improved progression-free and overall survival in extensive-stage SCLC, suggesting a new first-line maintenance standard. DELPHI-304 demonstrated ...